Haematology

Haematology
2024-02-29T00:00:00.000+00:00
Ongoing

MK4280a

MK4280a
Haematology

A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Trial overview

Disease

Haematology

Topic

Non Hodgkins lymphoma

Sponsor

MSD

Description

A Phase 3 Randomized Clinical Study of MK-4280A (Coformulated Favezelimab [MK-4280] Plus Pembrolizumab [MK-3475]) Versus Physician's Choice Chemotherapy in PD-(L)1-refractory, Relapsed or Refractory Classical Hodgkin Lymphoma (KEYFORM-008)

Study details

For detailed information on this trial, please click here

Trial status

Open

Location

Oxford :::

Priniciple Investigator

Professor Graham Collins

MBBS, MA, MRCP, FRCPath, DPhil

Haematology Consultant

Oxford